Analyst Tazeen Ahmad of Bank of America Securities maintained a Buy rating on Argenx Se (ARGX – Research Report), retaining the price target of $774.00.
Tazeen Ahmad has given his Buy rating due to a combination of factors including the promising outlook for Argenx’s commercial franchise and pipeline developments. The management highlighted the strong performance of Vyvgart in treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approximately 20 data readouts expected over the next 2.5 years. These developments represent significant opportunities for growth and expansion.
Furthermore, the introduction of a prefilled syringe (PFS) for Vyvgart is anticipated to drive continued growth by facilitating self-administration and expanding its use in earlier treatment lines. This innovation is expected to open up new patient and prescriber opportunities in the U.S. market. Additionally, the management’s focus on collaborations rather than acquisitions, along with their commitment to advancing new molecules into clinical trials, supports a positive long-term growth trajectory for the company.
In another report released on March 5, Morgan Stanley also maintained a Buy rating on the stock with a $715.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com